Close

European Medicines Agency Validates Bristol-Myers Squibb’s Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Top Books Every Aspiring Pharmacist Should Read

Foundations That Shape the Profession Every pharmacist begins with a...

LOTTE BIOLOGICS Enters Contract Manufacturing Collaboration

LOTTE BIOLOGICS, on September 1, 2025, announced that it...

Cook Medical Says Extra Tariff to Be Passed to US Customers

According to medical device firm Cook Medical, the costs...

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies...

“We are eager to continue to extend the use of Opdivo as a treatment option and potentially provide hematology with its first PD-1 inhibitor, a type of treatment that is designed to work with the PD-1 pathway and leverage the immune system to help fight classical Hodgkin lymphoma”

Bristol-Myers Squibb Company (NYSE:BMY) announced today that the European Medicines Agency (EMA) validated a type II variation application, which seeks to extend the current indications for Opdivo to include the treatment of patients with classical Hodgkin lymphoma (cHL) after prior therapies. The application included CheckMate -205 data, which evaluated Opdivo in cHL patients who have received autologous stem cell transplant and brentuximab vedotin. Validation of the application confirms the submission is complete and begins the EMA’s centralized review process.

“We are eager to continue to extend the use of Opdivo as a treatment option and potentially provide hematology with its first PD-1 inhibitor, a type of treatment that is designed to work with the PD-1 pathway and leverage the immune system to help fight classical Hodgkin lymphoma,” said Jean Viallet, M.D., Oncology Global Clinical Research Lead, Bristol-Myers Squibb. “We are hopeful to build on expanding our hematology franchise and bring the science of Immuno-Oncology to these adult relapsed and refractory classical Hodgkin lymphoma patients in Europe who often have limited remaining treatment options.”

CheckMate -205 is a Phase 2 study evaluating the safety and efficacy of Opdivo in patients with relapsed or refractory cHL. The results of this trial are expected to be presented at a medical meeting later this year.

 

Latest stories

Related stories

Top Books Every Aspiring Pharmacist Should Read

Foundations That Shape the Profession Every pharmacist begins with a...

LOTTE BIOLOGICS Enters Contract Manufacturing Collaboration

LOTTE BIOLOGICS, on September 1, 2025, announced that it...

Cook Medical Says Extra Tariff to Be Passed to US Customers

According to medical device firm Cook Medical, the costs...

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back